IP Library Granted Patent US 7,749,977
Granted Patent B2
US 7,749,977 · App. 11/586,021 · Granted Jul 6, 2010

Therapeutic modulation of the Fas pathway

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,749,977
App. No.
11/586,021
Granted
Jul 6, 2010
Kind
B2
Abstract

A method for the identification of genes that are essential for the maintenance of specific cell phenotypes is disclosed. The method includes the initial step of identifying a cell type with a phenotype of interest. Gene inactivation is performed on an aliquot of cells of the cell type of interest. Selection is then performed to an aliquot of the cell culture to which gene inactivation has been applied. Cells which continue to maintain the phenotype following gene inactivation have not had the gene of interest inactivated whereas cells in which genes necessary for maintaining the phenotype have been inactivated have been lost. Utilizing subtraction analysis between treated and untreated aliquots the gene in the cells which has been inactivated that affects the phenotype of interest is identified. Genes that are identified by the method are also disclosed as well as antibodies directed against the gene product of the identified genes. Further a customized kit for the practice of the gene identification method is also disclosed.

Claims (5)

1. A method of inducing apoptosis in a tumor cell of a subject comprising administering directly to the tumor cell an effective amount of an antisense compound or siRNA compound which hybridizes to a mRNA encoding Nrf2 so as to inhibit expression of the Nrf2 gene and induce apoptosis of the tumor cell.

2. The method according to claim 1 , wherein the compound is an siRNA.

3. The method according to claim 1 , wherein the compound is an antisense compound.

4. A method of sensitizing a tumor cell of a subject to chemotherapy associated with Fas induced apoptosis comprising administering directly to the tumor cell an effective amount of an antisense compound or an siRNA compound which hybridizes to a mRNA encoding Nrf2 so as to inhibit expression of the Nrf2 gene.

5. The method according to claim 4 , wherein the compound is an antisense compound or an siRNA.

Assignments (2)
DOCUMENT RE-RECORDED TO CORRECT ERRORS CTONAINED IN PROPERTY NUMBER(S) 10/671,921, 11/807,956, 10/579,669 AND 6,696,454. DOCUMENT PREVIOUSLY RECORDED ON REEL 020206 FRAME 0703. (ASSIGNMENT OF ASSIGNOR'S INTEREST) OR NATURE OF CONVEYANCE. Recorded Jan 12, 2009
From: QUARK BIOTECH, INC.
To: QUARK PHARMACEUTICALS, INC.
Reel/Frame 022191/0628 →
CHANGE OF NAME Recorded Dec 3, 2007
From: QUARK BIOTECH, INC.
To: QUARK PHARMACUTICALS, INC.
Reel/Frame 020206/0703 →